Business Context and Reporting Period
This Form 8-K is a current report filed by SELLAS Life Sciences Group, Inc. on June 2, 2026. The filing addresses "Other Events" (Item 8.01) regarding the company's cash position and capital structure updates subsequent to the March 31, 2026 quarter-end.
Key Financial Metrics
- Cash and Cash Equivalents (as of March 31, 2026): $107.1 million.
- Recent Proceeds (April and May 2026): Approximately $28.7 million received from the exercise of common stock warrants.
- Shares Outstanding (as of June 2, 2026): 196,632,574 shares of common stock.
- Revenue, Profit, and Margins: The filing text does not provide a clear value for these metrics.
- Debt and Liquidity: Specific debt figures are not disclosed in this report; liquidity is indicated by the cash balance and recent warrant proceeds.
Material Changes
The primary material change reported is the increase in cash resources due to the exercise of common stock warrants. Between April and May 2026, the company raised approximately $28.7 million, augmenting the $107.1 million cash balance held as of March 31, 2026. Additionally, the share count is confirmed at 196,632,574 as of the report date.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure of the warrant exercise event. No unusual items or contingencies are detailed in this specific report.
Investor Verification Checklist
- Verify the total cash position as of June 2, 2026, by adding the $28.7 million in warrant proceeds to the March 31, 2026 balance, accounting for any interim operating expenditures.
- Confirm the dilution impact of the warrant exercises on the 196,632,574 shares outstanding.
- Review the terms of the exercised warrants to understand the pricing and any remaining unexercised warrants.